Gland Pharma (Large Cap) Share Target 2024, 2025 To 2039
|
Gland Pharma Limited |
|||
|
Price: ₹1,772.30 | ||
| 52 Week Low: ₹1,585.70 52 Week High: ₹2,220.95 |
|||
| Market Capital: 29,441.18 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Gland Pharma Share Price Target For 2024
- 1.1.1: Gland Pharma Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Gland Pharma Share Price Target For 2025
- 1.2.1: Gland Pharma Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Gland Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Gland Pharma Brief Company Overview
- 4: Gland Pharma Financial Performance
- 4.0.1: Is Gland Pharma A Good Buy For Long Term?
To predict the Gland Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Gland Pharma Share Price Target For 2024
The line chart displays the monthly closing prices of Gland Pharma with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Gland Pharma shares in 2024, see the table below.
Gland Pharma Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1837.15 (+3.65%) | Price Action: 06 Dec 2024 High |
| 2024 Target 2 | 1817.6 (+2.55%) | Technical Indicator: MA100 |
| 2024 Target 1 | 1793.44 (+1.19%) | Price Action: 07 Nov 2024 Low |
| Current Price | 1772.30 | Gland Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1761.2 (-0.63%) | Price Action: 12 Dec 2024 Low |
| Stop Loss 2 | 1736.65 (-2.02%) | Price Action: 13 Dec 2024 Low |
| Stop Loss 3 | 1717.28 (-3.11%) | Price Action: Dec 2023 Low |
Short-Term Technical Outlook
Current Technical Position: Gland Pharma is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹1770.45 serves as the nearest technical reference point.
Historical Returns: 3-month: -1.31% | 6-month: -1.88% | 1-year: -6.96%
Gland Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Gland Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Gland Pharma shares in 2025, see the table below.
Gland Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2240.03 (+26.39%) | Price Action: Chart |
| 2025 Target 2 | 2198.26 (+24.03%) | Fibonacci Extension Level 100.00% |
| 2025 Target 1 | 2169.86 (+22.43%) | Fibonacci Extension Level 64.90% |
| Current Price | 1772.30 | Gland Pharma's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1663.34 (-6.15%) | Price Action: 25 Oct 2024 High |
| Stop Loss 2 | 1644.28 (-7.23%) | Price Action: May 2024 Low |
| Stop Loss 3 | 1623.8 (-8.38%) | Price Action: 31 Oct 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Gland Pharma is currently trading at 29.4% of its 52-week range (₹1585.7 - ₹2220.95).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -6.96% | 3-year: -53.67% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Gland Pharma Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,772.30 | ||
| 2024 | ₹1,749.46 | -1.29% | ₹1,800.37 |
| 2025 | ₹1,649.47 | -5.72% | ₹1,802.73 |
| 2026 | ₹1,578.67 | -4.29% | ₹1,720.57 |
| 2027 | ₹1,412.16 | -10.55% | ₹1,604.34 |
| 2028 | ₹1,405.45 | -0.48% | ₹1,488.11 |
| 2029 | ₹1,302.88 | -7.30% | ₹1,371.88 |
| 2030 | ₹1,205.76 | -7.45% | ₹1,340.59 |
| 2031 | ₹1,195.73 | -0.83% | ₹1,255.65 |
| 2032 | ₹1,413.64 | +18.22% | ₹1,587.67 |
| 2033 | ₹1,457.47 | +3.10% | ₹1,535.95 |
| 2034 | ₹1,404.39 | -3.64% | ₹1,484.23 |
| 2035 | ₹1,351.98 | -3.73% | ₹1,449.95 |
| 2036 | ₹1,332.34 | -1.45% | ₹1,432.50 |
| 2037 | ₹1,226.17 | -7.97% | ₹1,380.78 |
| 2038 | ₹1,258.92 | +2.67% | ₹1,329.06 |
| 2039 | ₹1,277.33 | +1.46% | ₹1,296.49 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Gland Pharma Brief Company Overview
Company Overview of Gland Pharma Limited Gland Pharma Limited, a pioneer in the pharmaceutical industry since 1978, is renowned for its expertise in manufacturing and distributing injectable formulations globally. Headquartered in Hyderabad, India, and backed by the...
strength of Fosun Pharma Industrial Pte. Ltd., Gland Pharma caters to a diverse range of markets, including the United States, Europe, Canada, and Australia. Their commitment to innovation is evident in their robust research and development initiatives, focused on pharmaceutical API products, including the synthesis of complex drug molecules. Gland Pharma offers a comprehensive portfolio of products spanning various therapeutic categories, meeting the needs of patients across the globe. Key Products and Services: Injectable formulations Pharmaceutical API products Contract development services Market Presence: India United States Europe Canada Australia New Zealand International Reputation: Gland Pharma Limited has consistently maintained a stellar reputation in the industry, recognized for its quality products, commitment to innovation, and customer-centric approach.Gland Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 29,441.18 Crore | Market valuation of Gland Pharma's shares. |
| Revenue (TTM) | 5,890.14 Crore | Total revenue generated by Gland Pharma over the past twelve months. |
| Net Income (TTM) | +6,915,689,984.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +14.45% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +11.74% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+2.40% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-15.70% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
3.71 | Company's total debt divided by total shareholder equity. |
| Total Debt | 326.62 Crore | Sum of Gland Pharma's current & long-term financial obligations. |
| Total Cash | 2,820.1 Crore | Total amount of liquid funds available to Gland Pharma. |
| Beta | 0.33 | Beta is less than 1 indicating that the Gland Pharma's price is less volatile than the market. |
Is Gland Pharma A Good Buy For Long Term?
Gland Pharma, a large-cap stock with a market capitalization of ₹29,441.18 Crore, shows mixed signals for long-term investment. While its ₹2,820.1 Crore cash balance and ₹691.56 Crore net profit (11.74% profit margin) in the last 12 months are positive, a 15.7% year-on-year decline in Q2 2024-25 earnings and negative returns over the past 3 months (-18.05%) and YTD (-8.81%) raise concerns. The 5-year return of 0.00% is also underwhelming. Considering these factors, Gland Pharma is currently an average buy, warranting further observation before a long-term commitment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
